Vascular Biogenics Ltd. (VBLT)
Stock Price:
$1.30 USD
0.04 (3.17%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
62.27M |
| Revenue (ttm) |
709,000 |
| Net Income (ttm) |
-20.63M |
| Shares Out |
47.90M |
| EPS (ttm) |
-0.57 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$1.30 |
| Previous Close |
$1.26 |
| Change ($) |
0.04 |
| Change (%) |
3.17% |
| Day's Open |
1.27 |
| Day's Range |
1.27 - 1.33 |
| Day's Volume |
172,550 |
| 52-Week Range |
0.90 - 1.64 |
More Stats
| Market Cap |
62.27M |
| Enterprise Value |
33.90M |
| Earnings Date (est) |
Aug 13, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
47.90M |
| Float |
20.41M |
| EPS (basic) |
0.58 |
| EPS (diluted) |
-0.57 |
| FCF / Share |
-0.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
302,130 |
| Short Ratio |
0.57 |
| Short % of Float |
0.88% |
| Beta |
0.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
87.82 |
| PB Ratio |
1.98 |
| Revenue |
709,000 |
| Operating Income |
-21.24M |
| Net Income |
-20.63M |
| Free Cash Flow |
-15.63M |
| Net Cash |
28.36M |
| Net Cash / Share |
0.59 |
| Gross Margin |
56.28% |
| Operating Margin |
-2,995.35% |
| Profit Margin |
-2,909.40% |
| FCF Margin |
-2,204.51% |
| ROA |
-25.70% |
| ROE |
-50.92% |
| ROIC |
-62.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.56*
(173.85% upside)
Low
2.50
Current: $1.30
High
5.00
Target: 3.56
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.56 | 0.59 | 13.86 | - | - | - | - | - |
| Revenue Growth | -3.93% | -95.78% | - | - | - | - | - | - |
| Gross Profit | 0.40 | 0.35 | 13.52 | - | - | - | - | - |
| Operating Income | -20.01 | -21.21 | -10.66 | -16.28 | -14.87 | -14.78 | -15.96 | -12.47 |
| Net Income | -19.46 | -20.46 | -10.14 | -16.00 | -14.89 | -17.41 | -17.37 | -12.23 |
| Shares Outstanding | 35.88 | 32.97 | 27.40 | 24.97 | 20.31 | 5.63 | 1.10 | 1.10 |
| Earnings Per Share | 0.54 | 0.62 | 0.37 | 0.64 | 0.73 | 3.09 | 15.82 | 11.13 |
| EPS Growth | -12.9% | 67.57% | -42.19% | -12.33% | -76.38% | -80.47% | 42.14% | - |
| Operating Cash Flow | -12.70 | -15.68 | -3.82 | -13.41 | -13.20 | -13.70 | -13.13 | -13.01 |
| Capital Expenditures | -0.07 | -2.23 | -6.48 | -0.49 | -0.09 | -0.06 | -0.03 | -0.16 |
| Free Cash Flow | -12.77 | -17.91 | -10.30 | -13.90 | -13.29 | -13.76 | -13.16 | -13.16 |
| Cash & Equivalents | 36.54 | 50.48 | 54.73 | 45.25 | 37.15 | 36.78 | 10.87 | 13.96 |
| Total Debt | 2.94 | 0.80 | - | - | - | - | 31.04 | - |
| Net Cash / Debt | 33.60 | 49.69 | 54.73 | 45.25 | 37.15 | 36.78 | -20.17 | 13.96 |
| Assets | 48.62 | 60.68 | 65.69 | 47.27 | 39.24 | 38.14 | 11.83 | 15.22 |
| Liabilities | 12.78 | 7.59 | 9.79 | 4.87 | 4.23 | 3.04 | 35.41 | 2.55 |
| Book Value | 35.84 | 53.09 | 55.90 | 42.40 | 35.01 | 35.10 | -23.58 | 12.67 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Vascular Biogenics Ltd. |
| Country |
Israel |
| Employees |
38 |
| CEO |
Dror Harats |
Stock Information
| Ticker Symbol |
VBLT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VBLT |
| IPO Date |
October 1, 2014 |
Description
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.